Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FASN | P49327 | 2/20 | 0.43 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.31 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25560389 | 0.75 | FASN (0.41) | FASNMTNR1AMTNR1BSMYD3 | |
| SCHEMBL25895252 | 0.73 | — | — | |
| SCHEMBL15199663 | 0.72 | FASN (0.36) | FASNMTNR1AMTNR1BSMYD3 | |
| SCHEMBL12207205 | 0.72 | FASN (0.36) | FASNMTNR1AMTNR1BSMYD3 | |
| SCHEMBL16252563 | 0.72 | FASN (0.36) | FASNMTNR1AMTNR1BSMYD3 | |
| SCHEMBL12206769 | 0.72 | FASN (0.36) | FASNMTNR1AMTNR1BSMYD3 | |
| SCHEMBL13035557 | 0.72 | EPHX2 (0.41) | FASNMTNR1AMTNR1B | |
| SCHEMBL12375166 | 0.72 | HSD11B1 (0.37) | — | |
| SCHEMBL25543871 | 0.72 | FASN (0.40) | FASNMTNR1AMTNR1BSMYD3 | |
| SCHEMBL18347982 | 0.71 | FASN (0.37) | FASNMTNR1AMTNR1BSMYD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2023-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233569-A1 | METHODS FOR DELAYING, PREVENTING, AND TREATING ACQUIRED RESISTANCE TO RAS INHIBITORS | KRAS, HRAS, MTOR | FASN 2848/4885MTNR1A 3842/4885MTNR1B 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.